Sign in

    Abbott Laboratories (ABT)

    Q2 2024 Earnings Summary

    Reported on Jan 10, 2025 (Before Market Open)
    Pre-Earnings Price$104.68Last close (Jul 17, 2024)
    Post-Earnings Price$102.39Open (Jul 18, 2024)
    Price Change
    $-2.29(-2.19%)

    What went well

    • Abbott has been delivering top-tier organic revenue growth over the past several quarters and expects to continue this trend into the future due to strong performance across all four business segments.
    • The Structural Heart division showed significant acceleration, with Amulet sales growing 45% in the U.S. this quarter, and strong performance from TriClip and Navitor, indicating broad-based growth and market share gains.
    • Innovation in Medical Devices, particularly with the Aveir leadless pacemaker system, is driving growth in previously flat businesses like Cardiac Rhythm Management, now growing at 7%, which could further increase with new product introductions.

    What went wrong

    • Litigation risks related to Necrotizing Enterocolitis (NEC) lawsuits concerning Abbott's preterm infant formula and human milk fortifier products could impact the company's reputation and financials, despite management downplaying the impact and stating that the issue is "way overblown".
    • In the Electrophysiology (EP) market, Abbott's growth of 17% is lower than the market growth, which is accelerating above 20%, indicating potential loss of market share and increased competition, especially with new product introductions affecting pricing dynamics.
    • Growth in historically slower-growing segments like Cardiac Rhythm Management (CRM) and Vascular heavily depends on the adoption of new technologies, such as the Aveir leadless pacemaker, which may face challenges in physician training and changing established procedures, potentially limiting growth acceleration in these areas ,.

    Q&A Summary

    1. Structural Heart Growth
      Q: What drove Structural Heart acceleration?
      A: Structural Heart accelerated this quarter, driven by broad-based growth across products like TriClip, Navitor, and Amulet. Early approval and launch of TriClip contributed significantly. Navitor is gaining traction due to its clinical profile and excellent hemodynamics. Amulet saw 45% U.S. growth, focusing on penetration within existing accounts.

    2. Sensor Business and Lingo
      Q: How are you segmenting Lingo vs. Rio?
      A: The strategy is to view sensors as a platform, expanding usage across different diabetes populations and into nondiabetic markets. The Libre continues to perform well, with significant growth opportunities remaining, especially among multiple daily injectors. Lingo aims at consumers without diabetes, focusing on behavior modification and healthier habits, representing a multibillion opportunity even with single-digit penetration.

    3. EP Business and PFA Impact
      Q: What's driving EP growth and PFA trends?
      A: The EP business grew 17% due to market acceleration and increased procedure volumes. The market is growing above 20%, fueled by new products like PFA. Though current penetration is around 10–15% internationally and stable, RF ablation remains important, especially for redo procedures. Abbott expects continued growth ahead of the Volt launch next year.

    4. Leadless Pacing with Aveir
      Q: Outlook for Aveir and leadless pacing?
      A: Leadless pacing with Aveir is expected to change CRM's growth trajectory. After two years, Abbott has captured about 50% share in single-chamber devices. Dual-chamber procedures are progressing well, and physician training is a focus to drive broader adoption. Leadless pacing presents a significant opportunity in the $3 billion global CRM market.

    5. Multiyear Growth Trajectory
      Q: Can you sustain top-tier growth without M&A?
      A: Abbott believes it can continue delivering top-tier growth organically, leveraging attractive markets, strong positions, and innovation. The last six quarters have shown high single-digit to double-digit growth. While M&A could further enhance growth, it's not dependent on it. Focus remains on strategic fit and attractive returns.

    6. Margin Expansion Outlook
      Q: Drivers behind expected margin expansion?
      A: Margin expansion is driven by portfolio contributions from top-line growth, particularly in accretive businesses. Abbott is back to prepandemic operating margin levels, focusing on gross margin improvements through productivity, yield enhancements, cost reductions, and innovation. Tailwinds include stabilizing commodities and normalized freight costs.

    7. Capital Allocation and M&A
      Q: Thoughts on M&A and capital allocation?
      A: Abbott maintains a balanced capital allocation approach, focusing on internal investments, debt paydown, dividends, and buybacks. With a strong balance sheet, the company can pursue M&A if strategic fits arise that generate attractive returns. Recent M&A activity in the sector is acknowledged, but Abbott remains selective.

    8. CRM and Vascular Growth
      Q: Sustainability of CRM growth and strategy?
      A: Abbott aims to accelerate CRM growth through innovation, focusing on leadless pacemakers like Aveir. The strategy includes pipeline expansion and potential innovations in ICDs. By revitalizing traditionally flat markets with new technology, Abbott expects CRM to contribute to higher medtech growth rates. Similar strategies are being applied to the Vascular business.

    9. Strategic Fit of Business Units
      Q: Any updates on business combinations or spins?
      A: Abbott continuously assesses its portfolio but believes the current diversification provides both defensive and offensive capabilities. All four sectors are delivering strong growth and innovation. While open to opportunities that create shareholder value, the focus remains on managing and growing the existing businesses effectively.

    10. Biosimilars Strategy
      Q: Elaborate on the biosimilars strategy.
      A: Abbott sees an opportunity to bring biologics to emerging markets where originators haven't focused. By partnering and leveraging its presence, Abbott aims to expand patient access without diluting gross margins. Launches are expected starting in 2025, with significant oncology opportunities in 2026–2027.

    11. Amulet Growth and Outlook
      Q: What's next for Amulet after 45% growth?
      A: Amulet achieved 45% U.S. growth, driven by penetration in existing centers. Abbott plans to continue expanding its sales force, entering new accounts, and investing in next-generation products focused on ease of use and sealing effectiveness. Clinical trials like CATALYST will support its value proposition.

    12. NEC Litigation Impact
      Q: Any updates on NEC litigation?
      A: Management believes the impact of the NEC litigation is overblown and is actively defending its position. They are working with stakeholders to communicate the situation's gravity as it progresses, with no further updates at this time.

    Related Publications